180 Life Sciences Corp. corrected errors in its previous filings regarding the conversion of Series B Convertible Preferred Stock and voting rights, with the correct conversion being 1,318,000 shares instead of 1,813,000 shares, and confirmed stockholder approvals from the Annual Meeting on December 27, 2024.